In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Endosense brings in €25mm through its Series B venture round

Executive Summary

Endosense (catheter ablation for cardiac arrhythmias) has raised €25mm ($36mm) through the closing of its Series B venture round. Edmond de Rothschild Investment Partners (EdRIP) led the financing and was joined by NeoMed, GIMV, VI Partners, Sectoral Asset Management, Ysios Capital Partners, and Initiative Capital Romandie. Endosense will use the money for European commercialization (it gained the CE Mark four months ago) and a US PMA study of its TactiCath ablation catheter. Representatives from EdRIP, GIMV, and VI will take seats on the company's board.

Deal Industry
  • Medical Devices
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies